QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:PALI

Palisade Bio (PALI) Stock Forecast, Price & News

$1.49
+0.07 (+4.93%)
(As of 06/6/2023 ET)
Compare
Today's Range
$1.40
▼
$1.53
50-Day Range
$1.32
▼
$3.52
52-Week Range
$1.27
▼
$30.60
Volume
239,704 shs
Average Volume
1.37 million shs
Market Capitalization
$9.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Palisade Bio MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Palisade Bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.57) to ($0.90) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

See Top Rated MarketRank™ Stocks Here

PALI stock logo

About Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

PALI Stock News Headlines

June 1, 2023 | finanznachrichten.de
Palisade Bio, Inc.: Palisade Bio Promotes J.D. Finley to Chief Executive Officer
June 1, 2023 | msn.com
Palisade Bio appoints J.D. Finley as permanent CEO
June 6, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
June 1, 2023 | finance.yahoo.com
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
May 28, 2023 | americanbankingnews.com
Analyzing Genocea Biosciences (NASDAQ:GNCAQ) & Palisade Bio (NASDAQ:PALI)
May 24, 2023 | finance.yahoo.com
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
May 23, 2023 | msn.com
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
May 19, 2023 | americanbankingnews.com
Palisade Bio (NASDAQ:PALI) Price Target Lowered to $16.00 at LADENBURG THALM/SH SH
June 6, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
May 18, 2023 | benzinga.com
Ladenburg Thalmann Maintains Buy on Palisade Bio, Lowers Price Target to $16
May 17, 2023 | finance.yahoo.com
PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST
May 17, 2023 | msn.com
Ladenburg Thalmann Maintains Palisade Bio (PALI) Buy Recommendation
May 13, 2023 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on Palisade Bio (PALI)
May 12, 2023 | finanznachrichten.de
Palisade Bio, Inc.: Palisade Bio Reports First Quarter 2023 Financial Results
May 12, 2023 | finance.yahoo.com
Palisade Bio Reports First Quarter 2023 Financial Results
May 11, 2023 | finance.yahoo.com
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
May 10, 2023 | americanbankingnews.com
Palisade Bio (PALI) to Release Earnings on Thursday
April 22, 2023 | marketwatch.com
S-1: PALISADE BIO, INC.
April 17, 2023 | finance.yahoo.com
Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
April 12, 2023 | benzinga.com
Premarket Mover: Palisade Bio Inc (PALI) Up 0.96%
April 6, 2023 | msn.com
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
April 6, 2023 | finance.yahoo.com
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
April 5, 2023 | marketwatch.com
Palisade Bio Shares Rise After First Patient Dosed With Gastrointestinal Drug
April 5, 2023 | finanznachrichten.de
Palisade Bio, Inc.: Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
April 5, 2023 | seekingalpha.com
Palisade Bio shares plummet following a $6M registered direct offering
April 5, 2023 | finance.yahoo.com
Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148
April 4, 2023 | marketwatch.com
Palisade Bio Shares Down for a Second Day, Declining 10%
See More Headlines

PALI Price History

PALI Company Calendar

Last Earnings
11/15/2021
Today
6/06/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PALI
CUSIP
N/A
CIK
1357459
Web
www.palisadebio.com
Phone
(858) 704-4900
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,260,000.00
Net Margins
N/A
Pretax Margin
-4,958.00%
Return on Equity
-115.68%
Return on Assets
-89.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.88
Quick Ratio
10.88

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
991.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.24 per share
Price / Book
0.35

Miscellaneous

Outstanding Shares
6,700,000
Free Float
6,613,000
Market Cap
$9.92 million
Optionable
Not Optionable
Beta
1.54

Key Executives

  • J. D. Finley
    Director, Chief Executive & Financial Officer
  • Robert McRae
    Chief Operating Officer
  • Ryker Willie
    Vice President-Finance & Controller
  • John Rodenrys
    Chief Technology Officer & Executive VP
  • Herbert B. Slade
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













PALI Stock - Frequently Asked Questions

Should I buy or sell Palisade Bio stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PALI shares.
View PALI analyst ratings or view top-rated stocks.

How have PALI shares performed in 2023?

Palisade Bio's stock was trading at $5.20 at the start of the year. Since then, PALI stock has decreased by 71.5% and is now trading at $1.4801.
View the best growth stocks for 2023 here.

Are investors shorting Palisade Bio?

Palisade Bio saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 114,600 shares, a decline of 65.0% from the April 30th total of 327,300 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.8% of the company's shares are sold short.
View Palisade Bio's Short Interest.

When is Palisade Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our PALI earnings forecast.

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) issued its quarterly earnings data on Monday, November, 15th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.78.

What is Palisade Bio's stock symbol?

Palisade Bio trades on the NASDAQ under the ticker symbol "PALI."

How do I buy shares of Palisade Bio?

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palisade Bio's stock price today?

One share of PALI stock can currently be purchased for approximately $1.48.

How much money does Palisade Bio make?

Palisade Bio (NASDAQ:PALI) has a market capitalization of $9.92 million and generates $10,000.00 in revenue each year.

How can I contact Palisade Bio?

Palisade Bio's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The official website for the company is www.palisadebio.com. The company can be reached via phone at (858) 704-4900 or via email at investor@senecabio.com.

This page (NASDAQ:PALI) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -